State Street SPDR S&P Pharmaceuticals ETF
XPH
60 hedge funds and large institutions have $204M invested in State Street SPDR S&P Pharmaceuticals ETF in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 7 closing their positions.
14,700% more call options, than puts
Call options by funds: $296K | Put options by funds: $2K
38.4% more ownership
Funds ownership: 71.85% → 110.25% (+38%)
32% more capital invested
Capital invested by funds: $154M → $204M (+$49.7M)
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
2% less funds holding
Funds holding: 61 → 60 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$33.1M |
| 2 |
JP Morgan Chase
New York
|
+$28.9M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$16.4M |
| 4 |
Goldman Sachs
New York
|
+$6.42M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.9M |
| 2 |
Morgan Stanley
New York
|
-$2.36M |
| 3 |
Jane Street
New York
|
-$1.16M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$831K |
| 5 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$666K |
XPH Hedge Fund Activity: Q3 2019 in Review
60 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2019, worth a combined $204M — up 32% from $154M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of XPH and 6 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 18 added.
The largest buyer was Bank of America, adding an estimated $33.1M. The largest seller was Deutsche Bank, exiting entirely with an estimated $13.9M sold.
- 60 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2019, down from 61 in Q2 2019.
- Funds reported $204M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2019, up 32% quarter-over-quarter.
- 6 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2019 and 7 closed out, a net change of -1 holder.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2019 was Bank of America, an estimated $33.1M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2019 was Deutsche Bank, an estimated $13.9M sold.
Based on aggregated 13F filings for Q3 2019.